Generic B — Competitive Intelligence Brief

Generic B (Generic B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-blocker. Area: Cardiovascular.

marketed beta-blocker beta-adrenergic receptors Cardiovascular Small molecule

Target snapshot

Generic B (Generic B) — University of Florida. Generic B is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Generic B TARGET	Generic B	University of Florida	marketed	beta-blocker	beta-adrenergic receptors
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Beta blocker/digoxine/amiodarone	Beta blocker/digoxine/amiodarone	Hospital Clinic of Barcelona	marketed	Combination antiarrhythmic/inotropic therapy	Beta-adrenergic receptors, Na+/K+-ATPase, cardiac ion channels (sodium, potassium, calcium)
Intravenous amiodarone(2)	Intravenous amiodarone(2)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels
Levophed	Norepinephrine Bitartrate	Pfizer Inc.	marketed	Catecholamine, sympathomimetic amine	Alpha-adrenergic and beta-adrenergic receptors
Ephedrine, continuous infusion	Ephedrine, continuous infusion	University of Parma	marketed	Sympathomimetic amine	Alpha and beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2035-02-26 — Levophed · 10251848 · Formulation · US
• 2035-02-26 — Levophed · RE49422 · Formulation · US
• 2035-02-26 — Levophed · RE49443 · Formulation · US
• 2038-01-30 — Levophed · 10226436 · Formulation · US
• 2038-01-30 — Levophed · 10568850 · Formulation · US
• 2038-01-30 — Levophed · 12245996 · Formulation · US
• 2038-01-30 — Levophed · 10159657 · Formulation · US
• 2038-01-30 — Levophed · 11413259 · Formulation · US
• 2038-01-30 — Levophed · 10420735 · Formulation · US
• 2038-01-30 — Levophed · 11602508 · Formulation · US
• 2039-04-26 — Levophed · 10888534 · Formulation · US
• 2041-03-08 — Levophed · 12097170 · Formulation · US
• 2041-03-08 — Levophed · 12290494 · Formulation · US

Sponsor landscape (beta-blocker class)

1. AstraZeneca · 1 drug in this class
2. University Hospital, Toulouse · 1 drug in this class
3. University of Florida · 1 drug in this class